药物设计的最新发展口服合成自由脂肪酸受体1激动剂
Lei Liu1,2, Qinghua Zhang1,2, Yichuan Ma3
1Tasly Academy, Tasly Pharma Co., Ltd., Tianjin, People's Republic of China.
Drug design, development and therapy
|December 16, 2024
概括
合成FFAR1激动剂在糖尿病和肝病方面表现有前途,但肝毒性仍然是一个挑战. 模仿天然产品的新型低分子量化合物提供了改善的肝脏安全性和潜在的治疗益处.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
- 肝病学 肝病学是一种肝病学.
背景情况:
- 合成FFAR1激动剂,包括TAK-875和TSL1806,已被广泛研究,但由于肝毒性,没有一个获得监管批准.
- 肝毒性可能与当前FFAR1主体结构中类似脂质的碳酸基团有关,这些基团可以形成有毒代谢物.
研究的目的:
- 探索减轻FFAR1激动剂肝毒性的策略.
- 研究新型低分子量化合物,提高安全性.
- 确定FFAR1激动剂在代谢和脑血管疾病中的潜在治疗应用.
主要方法:
- 对与FFAR1激动剂肝毒性相关的分子结构和代谢途径的审查.
- 开发低分子量化合物,降低脂友性和改变化学组.
- 临床试验评估新型FFAR1激动剂的肝脏安全性和有效性,例如CPL207280.
- 人工智能和计算机辅助设计在药物开发中的应用.
主要成果:
- 确定分子结构作为FFAR1激动剂诱导肝毒性的关键因素.
- 开发CPL207280,一个有前途的低分子量FFAR1激动剂,在II期试验中证明了肝脏的安全性.
- 探索FFAR1激动剂在治疗糖尿病,非酒精性脂肪性肝病 (NAFLD) 和脑血管疾病方面的潜在用途.
结论:
- 优化化学结构以减少脂性和防止有毒代谢物形成对于开发安全的FFAR1激动剂至关重要.
- 使用先进技术开发的模仿自然结构的紧分子,代表了未来FFAR1激动剂研究的有希望的途径.
- 在成功的安全性和有效性评估之前,FFAR1激动剂有可能治疗各种疾病,包括糖尿病,NAFLD和脑血管疾病.
相关概念视频
Drug-Receptor Interaction: Agonist
2.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.3K
Structure-Activity Relationships and Drug Design
510
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
510
Glucagon-like Receptor Agonists
297
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
297
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.6K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.6K
Principles of Drug Action
5.7K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
5.7K
Drug-Receptor Interactions
4.9K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
4.9K


